ERIS LifescienceQ1 FY25

ERIS Lifescience Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,361.3P/E: 25.3Market Cap: ₹18.9K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

No

Order

Yes

Capex

Yes

2 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Domestic Branded Formulations (DBF) revenue targeted at Rs. 2,600 crores with 12-14% organic growth in FY25.
  • Consolidated revenue expected to exceed Rs. 3,000 crores with an EBITDA margin of 35%.
  • Biocon business forecasted to grow 27% in revenue with a margin expansion of approximately 1,000 bps.
  • Swiss Parenterals aims for Rs. 330 crores revenue with 14% top-line growth and 30% EBITDA growth.
  • Insulin franchise (including Basalog, Insugen, Xsulin, Xglar) anticipated to reach Rs. 340-350 crores, a 40% growth on the acquired base.
  • Strong growth expected from super-specialty segments (Critical Care, Oncology, Nephrology) at 10%+ volume growth annually.
  • New product launches in Cardiology (Dapagliflozin plus Metoprolol and Dapagliflozin plus Bisoprolol) planned for Q2 to aid growth.
  • Margin expansion driven by productivity gains, gross margin improvement, and fixed cost synergies.

See what ERIS Lifescience management said on margin guidance — free account, 30 seconds.

Fundraise plans

No
  • No explicit mention of new fundraising through debt or equity in the provided excerpts.
  • Management emphasized "heads down execution" with no acquisitions unless the balance sheet improves, implying caution on new debt or equity raises.
  • Debt reduction is a priority, aiming to reduce Net Debt to Rs. 2,600 crores by FY25 end and around Rs. 2,000 crores by FY26.
  • Operating cash flow expected to fund capex and debt servicing, suggesting no immediate need for external fundraising.
  • Capex for biotech expansion and site acquisition is planned within existing financial guidance (Rs. 200 crores over FY25-26 for insulin, MAB, hormones).
  • Focus remains on rebuilding balance sheet strength rather than raising new funds at this time.

See what ERIS Lifescience management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Insulin manufacturing plant investment: Additional capex of Rs. 20-25 crores planned for the insulin piece at the acquired plant, included within the identified capex and not incremental. (Page 20)
  • Biotech segment capex: Rs. 100-120 crores additional capex envisaged for various Biotech segments including Insulin, MABs, and Hormones, with Rs. 200 crores planned over FY25 and FY26 for Insulin, MABs, and Hormone manufacturing combined. (Pages 8, 19)
  • Manufacturing lines: Plan to install six lines for Insulin (four for vials, two for cartridges), two lines for MABs, and additional hormone lines in early stages. Capex will spill over 2-3 years. (Page 18)
  • Site acquisition cost: Rs. 105 crores spent on site acquisition as part of the overall capex. (Page 8)
  • Focused on building new biotech capabilities rather than maintenance capex. (Page 17)

Track ERIS Lifescience — get its next earnings analysis in your feed

How does ERIS Lifescience rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisERIS Lifescience
Rev 3Mar 3

How does ERIS Lifescience rank in Pharmaceuticals & Biotechnology?

Compare ERIS Lifescience against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →